Nanobiotix to Present at Key November Investor Conferences

An announcement from Nanobiotix ( (NBTX) ) is now available.

On November 3, 2025, Nanobiotix announced its participation in several investor conferences scheduled for the week of November 10, 2025. The company’s management, including CEO Laurent Levy and CFO Bart van Rhijn, will present at the UBS Global Healthcare Conference, Guggenheim’s Annual Healthcare Innovation Conference, and the Stifel Healthcare Conference. These events are expected to enhance Nanobiotix’s visibility within the healthcare investment community and potentially attract new stakeholders.

The most recent analyst rating on (NBTX) stock is a Hold with a $20.50 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.

Spark’s Take on NBTX Stock

According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.

Nanobiotix faces significant financial difficulties, with negative profitability and a heavily leveraged balance sheet being the most critical factors. Technical analysis provides some short-term positive signals, but the valuation remains unattractive due to a negative P/E ratio and no dividend yield. These factors collectively result in a low overall stock score.

To see Spark’s full report on NBTX stock, click here.

More about Nanobiotix

Nanobiotix is a late-stage clinical biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases. Founded in 2003 and headquartered in Paris, France, the company is listed on Euronext Paris and the Nasdaq Global Select Market. Nanobiotix owns over 25 patent families related to nanotechnology platforms with applications in oncology, bioavailability, biodistribution, and central nervous system disorders.

Average Trading Volume: 83,398

Technical Sentiment Signal: Buy

Current Market Cap: $988.9M

Find detailed analytics on NBTX stock on TipRanks’ Stock Analysis page.